Publications for Tim Lambert
2016
Psychiatry, 20(3), 214-219. <a
href="http://dx.doi.org/10.1177/1039856212437
254">[More Information]</a>
Kritharides, L., Rye, K., Lambert, T., Jessup, W.
(2016). Lipidology, cardiovascular risk, and
schizophrenia. Current Opinion in Lipidology,
27(3), 305-307. <a
href="http://dx.doi.org/10.1097/MOL.00000000
00000307">[More Information]</a>
Robillard, R., Rogers, N., Whitwell, B., Lambert,
T. (2012). Are Cardiometabolic and Endocrine
Abnormalities Linked to Sleep Difficulties in
Schizophrenia? A Hypothesis Driven Review.
Clinical Psychopharmacology and Neuroscience,
10(1), 1-12.
2014
Feiler, G., Chen, R., Pantelis, C., Lambert, T.
(2012). Health behaviours of community-treated
patients with psychosis. Australasian Psychiatry,
20(3), 208-213. <a
href="http://dx.doi.org/10.1177/1039856211432
459">[More Information]</a>
Publications for Tim Lambert
O'Connor, N., Hunt, G., O'Hara-Aarons, M.,
Hall, A., Snars, J., Storm, V., Lambert, T.
(2014). The Sydney Mental Health Client
Mortality Audit: what does it tell us and what are
we to do? Australasian Psychiatry, 22(2),
154-159. <a
href="http://dx.doi.org/10.1177/1039856213519
690">[More Information]</a>
2013
Hibbert, E., Lambert, T., Carter, J., Learoyd, D.,
Twigg, S., Clarke, S. (2013). A randomized
controlled pilot trial comparing the impact of
access to clinical endocrinology video
demonstrations with access to usual revision
resources on medical student performance of
clinical endocrinology skills. BMC Medical
Education, 13(1), 1-10. <a
href="http://dx.doi.org/10.1186/1472-6920-13-1
35">[More Information]</a>
Lambert, T. (2013). Improving patient adherence
in schizophrenia and schizophrenia-related
disorders. International Clinical
Psychopharmacology, 28(Suppl1), S1-S2. <a
href="http://dx.doi.org/10.1097/YIC.0b013e3283
5ab250">[More Information]</a>
Chen, R., Lambert, T. (2013). Managing
cardiovascular risk factors in people with serious
mental illness: the tragedy of neglect.
Endocrinology Today: peer reviewed updates for
medical practitioners, 2(1), 25-27.
Kalucy, M., Grunstein, R., Lambert, T., Glozier,
N. (2013). Obstructive sleep apnoea and
schizophrenia - A research agenda. Sleep
Medicine Reviews, 17(5), 357-365. <a
href="http://dx.doi.org/10.1016/j.smrv.2012.10.0
03">[More Information]</a>
Lambert, T. (2013). Practical management of
schizophrenia: the role of long-acting
antipsychotics. International Clinical
Psychopharmacology, 28(Suppl 1), S16-S27. <a
href="http://dx.doi.org/10.1097/YIC.0b013e3283
5ab399">[More Information]</a>
2012
O'Connor, N., Mulley, R., Grasso, B., Lambert,
T., Snars, J., Jhita, P. (2012). An Acute Recovery
Unit: the first 18 months. Australasian
Lambert, T., Emmerson, B., Hustig, H., Resseler,
S., Jacobs, A., Butcher, B. (2012). Long acting
risperidone in Australian patients with chronic
schizophrenia: 24-month data from the e-STAR
database. BMC Psychiatry, 12(1), 1-8. <a
href="http://dx.doi.org/10.1186/1471-244X-12-2
5">[More Information]</a>
Robillard, R., Lambert, T., Rogers, N. (2012).
Measuring sleep-wake patterns with physical
activity and energy expenditure monitors.
Biological Rhythm Research, 43(5), 555-562. <a
href="http://dx.doi.org/10.1080/09291016.2011.
614794">[More Information]</a>
2011
Happell, B., Platania-Phung, C., Gray, R., Hardy,
S., Lambert, T., McAllister, M., Davies, C.
(2011). A role for mental health nursing in the
physical health care of consumers with severe
mental illness. Journal of Psychiatric and Mental
Health Nursing, 18(8), 706-711. <a
href="http://dx.doi.org/10.1111/j.1365-2850.201
0.01666.x">[More Information]</a>
Lambert, T., Olivares, J., Peuskens, J., DeSouza,
C., Kozma, C., Otten, P., Crivera, C., Jacobs, A.,
Macfadden, W., Mao, L., et al (2011).
Effectiveness of injectable risperidone
long-acting therapy for schizophrenia: data from
the US, Spain, Australia, and Belgium. Annals of
General Psychiatry, 10, 1-7. <a
href="http://dx.doi.org/10.1186/1744-859X-10-1
0">[More Information]</a>
Patel, M., Matonhodze, J., Baig, M., Gilleen, J.,
Boydell, J., Holloway, F., Taylor, D., Szmukler,
G., Lambert, T., David, A. (2011). Increased use
of antipsychotic long-acting injections with
community treatment orders. Therapeutic
Advances in Psychopharmacology, 1(2), 37-45.
<a
href="http://dx.doi.org/10.1177/2045125311407
960">[More Information]</a>
Lambert, T. (2011). Managing the metabolic
adverse effects of
Publications for Tim Lambert
antipsychotic drugs in patients with psychosis.
Australian Prescriber, 34(4), 97-99.
Lambert, T., Taylor, D. (2011). Pharmacology of
antipsychotic long-acting injections. In Peter
Haddad, Tim Lambert, John Lauriello (Eds.),
Antipsychotic Long-acting injections, (pp.
23-46). Oxford, United Kingdom: Oxford
University Press.
Lambert, T. (2011). Prescribing patterns and
determinants of use of antipsychotic long-acting
injections: an international perspective. In Peter
Haddad, Tim Lambert, John Lauriello (Eds.),
Antipsychotic Long-acting injections, (pp.
209-239). Oxford, United Kingdom: Oxford
University Press.
Dalton, A., Lambert, T., Schrover, R., Hertel, J.,
Kingsford Smith, D. (2011). The cost associated
with administering risperidone long-acting
injections in the Australian community. BMC
Health Services Research, 11(236), 1-9. <a
href="http://dx.doi.org/10.1186/1472-6963-11-2
36">[More Information]</a>
Haddad, P., Lambert, T., Lauriello, J. (2011).
The role of antipsychotic long-acting injections
in current practice. In Peter Haddad, Tim
Lambert, John Lauriello (Eds.), Antipsychotic
Long-acting injections, (pp. 241-260). Oxford,
United Kingdom: Oxford University Press.
Kelin, K., Lambert, T., Brnabic, A., Newton, R.,
Ye, W., Escamilla, R., Chen, K., Don, L.,
Montgomery, W., Karagianis, J., et al (2011).
Treatment discontinuation and clinical outcomes
in the 1-year naturalistic treatment of patients
with schizophrenia at risk of treatment
nonadherence. Patient Preference and
Adherence, 5, 213-222. <a
href="http://dx.doi.org/10.2147/PPA.S16800">[
More Information]</a>
McGorry, P., Cocks, J., Power, P., Burnett, P.,
Harrigan, S., Lambert, T. (2011). Very
Low-Dose Risperidone in First-Episode
Psychosis: A Safe and Effective Way to Initiate
Treatment. Schizophrenia Research and
Treatment, 2011, 631690-1-631690-10. <a
href="http://dx.doi.org/10.1155/2011/631690">[
More Information]</a>
<a
href="http://dx.doi.org/10.1016/j.biopsych.2009.
09.020">[More Information]</a>
Lambert, T. (2010). Office for Psychiatric
Evaluation and New Media (open). In Edmond
Chiu & Joy Preston (Eds.), The Department of
Psychiatry at the University of Melbourne
1964-2009: Personal Reminiscences, (pp.
130-134). Melbourne: University of Melbourne.
Ryder, A., Lambert, T., Blaszczynski, A. (2010).
The temporal stability and the determinants of
subjective well being under antipsychotic
medication in first-episode psychosis.
Schizophrenia Research, 117(Special Issue),
402-402. <a
href="http://dx.doi.org/10.1016/j.schres.2010.02.
730">[More Information]</a>
Ryder, A., Lambert, T., Blaszczynski, A. (2010).
The temporal stability and the determinants of
subjective well-being under antipsychotic
medication in first-episode psychosis. 2nd
Schizophrenia International Research Society, .:
Schizophrenia International Research Society.
2009
Lambert, T., Newcomer, J. (2009). Are the
cardiometabolic complications of schizophrenia
still neglected? Barriers to care. Medical Journal
of Australia, 190(4 Suppl), S39-S42. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=19220173">[More Information]</a>
Lambert, T., Singh, B., Patel, M. (2009).
Community treatment orders and antipsychotic
long-acting injections. British Journal of
Psychiatry, 195(52), S57-S62. <a
href="http://dx.doi.org/10.1192/bjp.195.52.s57">
[More Information]</a>
Lambert, T., Addington, J., Burnett, P. (2009).
Complete and incomplete recovery from first
-episode psychosis. In Patrick D McGorry,
Henry J Jackson (Eds.), The Recognition and
Management of Early Psychosis: A Preventive
Approach, (pp. 201-222). United Kingdom:
Cambridge University Press.
Lambert, T. (2010). Disease Management:
Multidimensional Approaches to Incomplete
Recovery in Psychosis. In H Elkis, H Meltzer
(Eds.), Therapy-Resistant Schizophrenia, (pp.
87-113). Basel: S. Karger AG.
Lambert, T. (2009). Switching to aripiprazole
from olanzapine leads to weight loss in
overweight people with schizophrenia or
schizoaffective disorder. Evidence-Based Mental
Health, 12(2), 50. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=19395609">[More Information]</a>
Guastella, A., Einfeld, S., Gray, K., Rinehart, N.,
Tonge, B., Lambert, T., Hickie, I. (2010).
Intranasal Oxytocin Improves Emotion
Recognition in Youth with Autism Spectrum
Disorders. Biological Psychiatry, 67, 692-694.
Lambert, T. (2009). The medical care of people
with psychosis. Medical Journal of Australia,
190(4), 171-172. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
2010
Publications for Tim Lambert
&list_uids=19220177">[More Information]</a>
2008
Sundram, S., Lambert, T., Piskulic, D. (2008).
Acculturation is associated with the prevalence
of tardive dyskinesia and akathisia in
community-treated patients with schizophrenia.
Acta Psychiatrica Scandinavica, 117(6),
474-478. <a
href="http://dx.doi.org/10.1111/j.1600-0447.200
8.01183.x">[More Information]</a>
Lauriello, J., Lambert, T., Andersen, S., Lin, D.,
Taylor, C., McDonnell, D. (2008). An 8-Week,
Double-Blind, Randomized, Placebo-Controlled
Study of Olanzapine Long-Acting Injection in
Acutely Ill Patients With Schizophrenia. Journal
Of Clinical Psychiatry, 69(5), 790-799. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18452346">[More Information]</a>
Lambert, T. (2008). Drug delivery systems in
schizophrenia. In Martin Lambert, Dieter Naber
(Eds.), Current Schizophrenia, (pp. 12-18).
London: Current Medicine Group Ltd.
Lambert, T., Norman, T. (2008). Ethnic
differences in psychotropic drug response and
pharmacokinetics. In Chee H. Ng, Keh-Ming
Lin, Bruce S. Singh, Edmond Y. K. Chiu (Eds.),
Ethno-psychopharmacology: Advances in
Current Practice, (pp. 38-61). Cambridge, UK:
Cambridge University Press.
Lambert, T., Detke, H., McDonnell, D.,
Lauriello, J., Anderson, S. (2008). Olanzapine
long-acting injection: An 8-week double-blind,
randomized, placebo-controlled study in
acutely-ill patients with schizophrenia.
International Journal of
Neuropsychopharmacology, 11, 152-152.
Walter, G., DeLaroche, A., Soh, N., Hunt, G.,
Cleary, M., Malhi, G., Lambert, T., Correll, C.,
Rey, J. (2008). Side effects of second-generation
antipsychotics: the experiences, views and
monitoring practices of
Australian child psychiatrists. Australasian
Psychiatry, 16(4), 253-262. <a
href="http://dx.doi.org/10.1080/1039856080195
8549">[More Information]</a>
2007
Iqbal, N., Lambert, T., Masand, P. (2007).
Akathisia: problem of history or concern of
today. CNS Spectrums, 12(Suppl 14), 9-1-9-13.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17805218">[More Information]</a>
Elsom, S., Happell, B., Manias, E., Lambert, T.
(2007). Expanded practice roles for community
mental health nurses: a qualitative exploration of
psychiatrists' views. Australasian Psychiatry,
15(4), 324-328. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17612887">[More Information]</a>
Subramaniam, M., Ng, C., Chong, S.,
Mahendran, R., Lambert, T., Pek, E., Huak, C.
(2007). Metabolic differences between Asian and
Caucasian patients on clozapine treatment.
Human Psychopharmacology-Clinical and
Experimental, 22(4), 217-222. <a
href="http://dx.doi.org/10.1002/hup.842">[More
Information]</a>
Berk, M., Fitzsimons, J., Lambert, T., Pantelis,
C., Kulkarni, J., Castle, D., Ryan, E., Jespersen,
S., McGorry, P., Berger, G., et al (2007).
Monitoring the Safe Use of Clozapine: A
Consensus View from Victoria, Australia. CNS
Drugs, 21(2), 117-127. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17284094">[More Information]</a>
Lambert, T. (2007). Switching antipsychotic
therapy: what to expect and clinical strategies for
improving therapeutic outcomes. Journal Of
Clinical Psychiatry, 68(Suppl 6), 10-13. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17650054">[More Information]</a>
Weiden, P., Miller, A., Lambert, T., Buckley, P.
(2007). The art and science of switching
antipsychotic medications, part 2. Journal of
Clinical Psychiatry, 68(1), e02. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17284123">[More Information]</a>
2006
Castle, D., Lambert, T., Melbourne, S., Cox, A.,
Boardman, G., Fairest, K., Davey, M., Goh, J.,
Kuluris, B., Berk, M. (2006). A clinical
monitoring system for clozapine. Australasian
Psychiatry, 14(2), 156-168. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16734644">[More Information]</a>
Lambert, T. (2006). Atypical antipsychotics in
schizophrenia. Medicine Today, 7(1), 55-58.
Lambert, T. (2006). Selecting patients for
long-acting novel antipsychotic therapy.
Australasian Psychiatry, 14(1), 38-42. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16630195">[More Information]</a>
2005
Fitzsimons, J., Berk, M., Lambert, T., Bourin,
Publications for Tim Lambert
M., Dodd, S. (2005). A review of clozapine
safety. Expert Opinion on Drug Safety, 4(4),
731-744.
Ng, C., Chong, S., Lambert, T., Fan, A., Hackett,
L., Mahendran, R., Subramaniam, M.,
Schweitzer, I. (2005). An inter-ethnic
comparison study of clozapine dosage, clinical
response and plasma levels. International
Clinical Psychopharmacology, 20(3), 163-168.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15812267">[More Information]</a>
Conley, R., Kelly, D., Lambert, T., Love, R.
(2005). Comparison of Clozapine Use in
Maryland and in Victoria, Australia. Psychiatric
Services, 56(3), 320-323. <a
href="http://dx.doi.org/10.1176/appi.ps.56.3.320
">[More Information]</a>
McGorry, P., Killackey, E., Lambert, T.,
Lambert, M., Royal Australian and New Zealand
College of Psychiatrists Clinical Practice, G.
(2005). Royal Australian and New Zealand
College of Psychiatrists clinical practice
guidelines for the treatment of schizophrenia and
related disorders. Australian and New Zealand
Journal of Psychiatry, 39(1-2), 1-30. <a
href="http://dx.doi.org/10.1111/j.1440-1614.200
5.01516.x">[More Information]</a>
2004
Humberstone, V., Wheeler, A., Lambert, T.
(2004). An audit of outpatient antipsychotic
usage in the three health sectors of Auckland,
New Zealand. Australian and New Zealand
Journal of Psychiatry, 38(4), 240-245.
Lambert, T., Chapman, L., Bell, J., Carr, N.,
D'Emden, M., Elsom, S., Groom, G., Henderson,
S., Hickie, I., Hoffman, L., Meagher, J., et al
(2004). Diabetes, psychotic disorders and
antipsychotic therapy: a consensus statement.
Medical Journal of Australia, 181(10), 544-548.
Lambert, T., Kelly, D., Alcock, S., Conley, R.
(2004). Letter To the Editor: Psychotropic
Prescribing for Acute Inpatient Admissions in
Patients with Severe Psychosis. Journal of
Clinical Psychopharmacology, 24(1), 91-93.
Lambert, T. (2004). The value of psychiatric
knowledge and expertise for general medical
doctors. Emergency Psychiatry, 7, 35-38.
2003
Pantelis, C., Lambert, T. (2003). Managing
patients with "treatment-resistant" schizophrenia.
Medical Journal of Australia, 178(9
Supplement), S62-S66.
Lambert, T., Cock, N., Alcock, S., Kelly, D.,
Conley, R. (2003). Measurement of
antipsychotic-induced side effects: Support for
the validity of a self-report (LUNSERS) versus
structured interview (UKU) approach to
measurement. Human
Psychopharmacology-Clinical and
Experimental, 18(5), 405-411. <a
href="http://dx.doi.org/10.1002/hup.495">[More
Information]</a>
Lambert, T., Velakoulis, D., Pantelis, C. (2003).
Medical comorbidity in schizophrenia. Medical
Journal of Australia, 178(9 Supplement),
S67-S70.
Gureje, O., Miles, W., Keks, N., Grainger, D.,
Lambert, T., McGrath, J., Tran, P., Catts, S.,
Fraser, A., Hustig, H., et al (2003). Olanzapine
vs risperidone in the management of
schizophrenia: a randomized double-blind trial in
Australia and New Zealand. Schizophrenia
Research, 61(2-3), 303-314.
Lambert, T., Brennan, A., Castle, D., Kelly, D.,
Conley, R. (2003). Perception of Depot
Antipsychotics by Mental Health Professionals.
Journal of Psychiatric Practice, 9(3), 252-260.
Lambert, T., Castle, D. (2003). Pharmacological
approaches to the management of schizophrenia.
Medical Journal of Australia, 178(9
Supplement), S57-S61.
Lambert, M., Conus, P., Lambert, T., McGorry,
P. (2003). Pharmacotherapy of first-episode
psychosis. Expert Opinion on Pharmacotherapy,
4(5), 717-750.
McGorry, P., Killackey, E., Elkins, K., Lambert,
M., Lambert, T. (2003). Summary Australian and
New Zealand clinical practice guideline for the
treatment of schizophrenia (2003). Australasian
Psychiatry, 11(2), 136-147.